Advertisement

Topics

Chugai Pharmaceutical Co., Ltd Company Profile

04:34 EST 19th December 2018 | BioPortfolio

Chugai Pharmaceutical Co., Ltd. places tremendous importance on the safekeeping of personal information obtained from customers using our website (information that is personally identifiable such as your name, address, e-mail address, or phone number, and that is not otherwise publicly available). Based on our Privacy Policy the following regulations have been implemented to insure that this information is strictly safeguarded and that the utmost care is given to the handling of the information.

Contact

Email: pr@chugai-pharm.co.jp


News Articles [249 Associated News Articles listed on BioPortfolio]

Chugai Pharmaceutical to expand Singaporean research subsidiary

Japan-based Chugai Pharmaceutical has revealed plans to expand its research subsidiary in Singapore, Chugai Pharmabody Research (CPR), in order to...Read More... The post Chugai Pharmaceutical to expa...

Results of Global Phase III Study with Chugai's HEMLIBRA® for Hemophilia A Without Inhibitors ...

For MediaChugai Pharmaceutical Co., Ltd.Media Relations Group, Corporate Communications Dept.,Tomoko ShimizuTel: +81-3-3273-0881E-mail: pr@chugai-pharm.co.jp***For US mediaChugai ...

Announcement of Business Expansion of Chugai Pharmabody Research Pte. Ltd., Chugai’s Research Subsidiary

TOKYO–(BUSINESS WIRE)–#antibody—Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that it has decided to expand the business of Chugai Pharmabody Research Pte. Ltd. (herei...

Lilly Licenses Chugai Pharma's Oral Diabetes Drug for $50 Million Upfront

Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.

Chugai Pharmaceutical Co., Ltd. Strategy, SWOT and Corporate Finance Report [Report Updated: 15102018] Prices from USD $175

Chugai Pharmaceutical Co., Ltd. Strategy, SWOT and Corporate Finance ReportSummaryChugai Pharmaceutical Co., Ltd. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company da...

HEMLIBRA von Chugai erhält von der US-amerikanischen FDA behördliche Zulassung für Hämophilie A ohne Inhibitoren

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) gab heute bekannt, dass die US-amerikanische Behörde für Lebensmittel- und Arzneimittelsicherheit (Food and Drug Administration, FDA) HEMLIBRA (in den .....

Taiwan OKs Chugai's Hemlibra to treat hemophilia A with inhibitors

The Taiwan Food and Drug Administration approved Hemlibra from Chugai Pharmaceutical to prevent bleeding episodes in patients -More- 

Lilly and Chugai in Diabetes Drug Pact

Eli Lilly has entered into an agreement with Chugai Pharmaceutical for the Japanese drugmaker’s oral non-peptidic GLP-1 receptor agonist OWL833, which is currently being developed for type 2 dia...

PubMed Articles [502 Associated PubMed Articles listed on BioPortfolio]

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.

Hemophilia A is an X-linked bleeding disorder caused by defects in the gene encoding factor VIII (FVIII). Routine prophylaxis with exogenous FVIII requires frequent intravenous injections. One of the ...

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.

Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expend...

Applications of various analytical techniques in quality control of pharmaceutical excipients.

Although excipients are pharmacologically inert substances, still they are integral and significant ingredients of a pharmaceutical formulation. Their amount and concentration level along with the act...

Applications of proteomics in pharmaceutical research and development.

The significance of proteomics in the pharmaceutical industry has increased since overcoming initial difficulties. This review discusses recent proteomics publications from pharmaceutical companies to...

Solid-state insight into the action of a pharmaceutical solvate: structural, thermal and dissolution analysis of indinavir sulfate ethanolate.

The crystal structure of indinavir sulfate, a pharmaceutical administered as an ethanol solvate, is presented, revealing a unique channel/ionic solvate structure to be characteristic of the compound. ...

Clinical Trials [334 Associated Clinical Trials listed on BioPortfolio]

Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home

The implementation of pharmaceutical consultations in the city or at the hospital could modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after return...

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to th...

Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program

The aim of the project is to evaluate effectiveness of a multidimensional pharmaceutical care plan in improving compliance among elderly polypharmacy users at community pharmacy settings. ...

Impact of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older

The primary objective of this study is to evaluate the impact of the implementation of collaborative pharmaceutical care on drug support at admission for patients 65 years of age and older...

Companies [1054 Associated Companies listed on BioPortfolio]

Chugai Pharma Europe Ltd

Chugai Pharmaceutical Co., Ltd is headquartered in Tokyo, Japan. In its home market, Chugai is a household name, with a broad-ranging product portfolio encompassing highly specialised therapeutic anti...

Chugai Pharma Europe Limited

European headquarters of Chugai Pharmaceutical Co. Ltd. and Chugai Pharma UK Ltd.

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical Co., Ltd. places tremendous importance on the safekeeping of personal information obtained from customers using our website (information that is personally identifiable such as y...

Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Company Limited

BioHealthcare Oncology

More Information about "Chugai Pharmaceutical Co., Ltd" on BioPortfolio

We have published hundreds of Chugai Pharmaceutical Co., Ltd news stories on BioPortfolio along with dozens of Chugai Pharmaceutical Co., Ltd Clinical Trials and PubMed Articles about Chugai Pharmaceutical Co., Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chugai Pharmaceutical Co., Ltd Companies in our database. You can also find out about relevant Chugai Pharmaceutical Co., Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record